Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Sales and Divestitures: 2012-2016

Historic Gains from Sales and Divestitures for Agios Pharmaceuticals (AGIO) over the last 4 years, with Dec 2016 value amounting to $7,500.

  • Agios Pharmaceuticals' Gains from Sales and Divestitures fell 11.99% to $7,500 in Q4 2016 from the same period last year, while for Dec 2016 it was $7,500, marking a year-over-year decrease of 11.99%. This contributed to the annual value of $7,500 for FY2016, which is 11.99% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $7,500 for Q4 2016, which was down 0.00% from $7,500 recorded in Q3 2016.
  • Over the past 5 years, Agios Pharmaceuticals' Gains from Sales and Divestitures peaked at $183,713 during Q4 2012, and registered a low of $2,841 during Q1 2015.
  • Its 3-year average for Gains from Sales and Divestitures is $8,171, with a median of $7,500 in 2016.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 90.55% in 2014, then spiked by 32.02% in 2016.
  • Agios Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $183,713 in 2012, then fell by 25.56% to $136,758 in 2013, then tumbled by 89.20% to $14,773 in 2014, then plummeted by 42.31% to $8,522 in 2015, then fell by 11.99% to $7,500 in 2016.
  • Its last three reported values are $7,500 in Q4 2016, $7,500 for Q3 2016, and $7,500 during Q2 2016.